Acumen Pharmaceuticals, Inc.
- Open
- 2.65
- Day high
- 2.70
- Day low
- 2.50
- Prev close
- 2.67
- Volume
- 106K
- Mkt cap
- $185M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.1
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$90K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
Acumen Pharmaceuticals, Inc. (ABOS) is a Healthcare company listed on NASDAQ. The stock is up 141% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Acumen Pharmaceuticals, Inc. (ABOS) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ABOS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.40 | $-0.33 | +18.1% | — | — |
| Mar 26, 2026 | $-0.50 | $-0.41 | +18.0% | — | — |
| Nov 12, 2025 | $-0.63 | $-0.44 | +30.2% | — | — |
| Aug 12, 2025 | $-0.54 | $-0.68 | -25.9% | — | — |
| Mar 27, 2025 | $-0.47 | $-0.62 | -31.9% | — | — |
| Aug 13, 2024 | $-0.28 | $-0.34 | -21.4% | — | — |
| Nov 14, 2022 | $-0.27 | $-0.26 | +3.7% | — | — |
| Aug 15, 2022 | $-0.24 | $-0.25 | -4.2% | — | — |
| May 16, 2022 | $-0.17 | $-0.23 | -35.3% | — | — |
| Nov 15, 2021 | $-0.21 | $-0.10 | +52.4% | — | — |
| Aug 16, 2021 | $-4.56 | $-7.91 | -73.5% | — | — |
ABOS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 17, 2026 | Porter Derrelldirector | Option | 6,460 | $1.07 |
| Jun 17, 2026 | Porter Derrelldirector | Option | 13,040 | $1.07 |
| Jun 17, 2026 | Porter Derrelldirector | Sell | 13,040 | $2.33 |
| Jun 17, 2026 | Porter Derrelldirector | Sell | 12,800 | $2.33 |
| Jun 17, 2026 | Porter Derrelldirector | Sell | 6,460 | $2.35 |
| Jun 10, 2026 | Fountain Nathan Bdirector | Sell | 6,400 | $2.23 |
| Jun 5, 2026 | Ives Jeffrey L.director | Grant | 53,250 | $2.29 |
| Jun 5, 2026 | Stalfort John A IIIdirector | Grant | 35,500 | — |
| Jun 5, 2026 | Porter Derrelldirector | Grant | 53,250 | $2.29 |
| Jun 5, 2026 | Porter Derrelldirector | Grant | 35,500 | — |
| Jun 5, 2026 | Stalfort John A IIIdirector | Grant | 53,250 | $2.29 |
| Jun 5, 2026 | Fountain Nathan Bdirector | Grant | 53,250 | $2.29 |
| Jun 5, 2026 | Fountain Nathan Bdirector | Grant | 35,500 | — |
| Jun 5, 2026 | Drapkin Kimberlee Cdirector | Grant | 35,500 | — |
| Jun 5, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Grant | 53,250 | $2.29 |
Source: ABOS SEC Form 4 filings, latest Jun 17, 2026. For informational purposes only — not investment advice.
See the full ABOS insider & 13F page →Acumen Pharmaceuticals, Inc. company profile
Overview
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Charlottesville, Virginia. The company went public in July 2021 and focuses exclusively on developing innovative treatments for Alzheimer's disease. Acumen has spent over two decades researching and developing targeted immunotherapy approaches, with its lead drug candidate sabirnetug (formerly ACU193) currently in Phase 2 clinical trials. The company represents a specialized player in the competitive Alzheimer's therapeutics landscape, pursuing a differentiated approach by targeting toxic amyloid-beta oligomers rather than amyloid plaques.
Business
Acumen Pharmaceuticals operates in the biotechnology sector, specifically focused on developing treatments for Alzheimer's disease, a progressive neurodegenerative disorder that affects millions of people worldwide. Alzheimer's disease is characterized by the accumulation of abnormal proteins in the brain, including amyloid-beta plaques and tau tangles, which lead to memory loss, cognitive decline, and eventual death. The company's core product is sabirnetug (previously known as ACU193), a humanized monoclonal antibody designed to target and neutralize soluble amyloid-beta oligomers. Unlike traditional approaches that target amyloid plaques (large protein deposits), sabirnetug focuses on oligomers, which are smaller, toxic protein clusters believed to be more directly responsible for nerve cell damage and cognitive decline in early-stage Alzheimer's disease. Monoclonal antibodies are laboratory-created proteins that can bind to specific targets in the body. In this case, sabirnetug is engineered to recognize and attach to amyloid-beta oligomers, potentially preventing them from damaging brain cells. The drug can be administered both intravenously (through IV infusion) and subcutaneously (under-the-skin injection), with the company developing both formulations to provide treatment flexibility. Acumen operates as a single-segment business focused entirely on Alzheimer's therapeutics, with 100% of its research and development efforts concentrated on advancing sabirnetug through clinical trials toward potential FDA approval and commercialization.
Revenue model
As a clinical-stage biopharmaceutical company, Acumen Pharmaceuticals currently generates no revenue and operates on a research and development investment model typical of early-stage biotech companies. The company's future business model will depend on successfully bringing sabirnetug to market, at which point it would generate revenue through product sales to healthcare providers, hospitals, and specialty clinics that treat Alzheimer's patients. The target customer base would include neurologists, geriatricians, and memory care specialists who treat patients with early-stage Alzheimer's disease, specifically those with mild cognitive impairment or mild dementia. Given the specialized nature of Alzheimer's treatment and the need for careful patient monitoring, sabirnetug would likely be distributed through specialty pharmacy networks and administered in clinical settings. Several factors could significantly impact Acumen's future profitability and margins. Positive factors include the large and growing Alzheimer's patient population (over 6 million Americans), limited effective treatment options creating significant unmet medical need, potential premium pricing for breakthrough therapies, and the company's differentiated mechanism of action that may offer improved safety profiles compared to competitors. The development of a subcutaneous formulation could also provide competitive advantages through improved patient convenience and reduced healthcare system burden. Negative factors that could pressure margins include intense competition from established pharmaceutical giants like Biogen and Eisai (which have approved Alzheimer's drugs), high manufacturing costs for complex monoclonal antibodies, extensive regulatory requirements and post-market surveillance costs, potential safety concerns that could limit market adoption, and reimbursement challenges given the high cost of specialized biologics. Additionally, the company faces the risk that sabirnetug may not demonstrate sufficient efficacy in Phase 2 trials, which would eliminate future revenue potential entirely.
Competitive moat
Acumen Pharmaceuticals operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this stage of development. The company's primary potential moat lies in its differentiated scientific approach of targeting soluble amyloid-beta oligomers rather than amyloid plaques, which could theoretically provide superior efficacy and safety compared to approved competitors like Leqembi and Aduhelm. However, this moat is largely theoretical and unproven until Phase 2 results demonstrate clear clinical benefits. The company's intellectual property portfolio around oligomer-targeting antibodies provides some protection, but patents in biotechnology can be challenged and worked around by well-resourced competitors. Acumen's relatively small size and limited resources compared to pharmaceutical giants like Roche, Biogen, and Eli Lilly also limits its ability to defend market position through extensive clinical programs or marketing capabilities. The most significant competitive threats come from larger pharmaceutical companies with greater financial resources, established regulatory expertise, and existing commercial infrastructure for launching Alzheimer's treatments. Companies like Eisai and Biogen already have approved products and are advancing next-generation therapies that could potentially offer similar or superior benefits to sabirnetug. Additionally, the field is witnessing rapid innovation in areas like combination therapies, earlier intervention strategies, and alternative mechanisms of action that could make oligomer-targeting approaches obsolete. The company's moat strength is currently weak to moderate, heavily dependent on clinical trial outcomes and the ability to demonstrate meaningful differentiation from existing and pipeline competitors. Success in Phase 2 trials could strengthen this position, but failure would likely eliminate any competitive advantages entirely.
Risks & safety
Acumen Pharmaceuticals presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant execution risks. **Cash Position and Solvency:** • Strong cash position of $197.9 million as of Q1 2025, providing runway into early 2027 • Minimal debt with debt-to-equity ratio of 0.19 • Excellent current ratio of 8.0 indicating strong short-term liquidity • Annual cash burn of approximately $86-100 million based on recent trends • No immediate solvency concerns given current cash runway **Valuation Metrics:** • Trading at 0.43x price-to-book ratio, suggesting potential undervaluation relative to assets • Negative earnings and EBITDA make traditional valuation metrics less relevant • Market cap of approximately $73 million appears modest for a Phase 2 biotech with significant cash holdings • Graham net-net ratio of 1.66 indicates trading below net current asset value **Other Considerations:** • Binary risk profile - success or failure in Phase 2 trials will dramatically impact valuation • Limited diversification with single drug candidate creates concentration risk • Strong balance sheet provides cushion for potential setbacks or extended development timelines • Potential upside significant if sabirnetug demonstrates efficacy, but downside risk substantial if trials fail
Recent development
Over the past few years, Acumen has executed a focused clinical development strategy centered on advancing sabirnetug through critical Phase 1 and Phase 2 milestones. The company successfully completed its INTERCEPT-AD Phase 1 study, which demonstrated positive safety results and target engagement, providing the foundation for larger-scale testing. This study showed dose-dependent target engagement of amyloid-beta oligomers and favorable biomarker effects, including reductions in amyloid plaques and improvements in cerebrospinal fluid markers. Building on Phase 1 success, Acumen launched the pivotal ALTITUDE-AD Phase 2 study in May 2024, rapidly enrolling 542 participants across over 75 sites in North America, the UK, and EU. The company significantly accelerated enrollment by implementing innovative screening procedures using plasma phospho-tau 217 biomarkers, improving the percentage of eligible patients from 40% to 81% compared to traditional screening methods. This efficiency gain demonstrates the company's operational capabilities and understanding of patient identification challenges in Alzheimer's research. Simultaneously, Acumen has pursued a dual formulation strategy, developing both intravenous and subcutaneous versions of sabirnetug. The company completed a Phase 1 subcutaneous study in 2024, exploring the potential for more convenient at-home or outpatient administration that could improve patient compliance and reduce healthcare system burden. This strategic move positions sabirnetug competitively against existing IV-only treatments. The company has also strengthened its leadership team by appointing Dr. Amy Schacterle as Chief Regulatory Officer and has actively engaged the scientific community through presentations at major conferences including AAIC, ADPD, and AAN. These efforts have focused on highlighting sabirnetug's differentiated mechanism and potential advantages in biomarker profiles, particularly around synaptic biomarkers that may indicate neuroprotective effects.
ABOS company profile · for informational purposes only — not investment advice.
Track ABOS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free